Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Enrolling by invitation Phase 3 Interventional

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

ClinicalTrials.gov ID: NCT06679946

Public ClinicalTrials.gov record NCT06679946. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Study identification

NCT ID
NCT06679946
Recruitment status
Enrolling by invitation
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alnylam Pharmaceuticals
Industry
Enrollment
700 participants

Conditions and interventions

Interventions

  • Vutrisiran Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2, 2024
Primary completion
Mar 30, 2028
Completion
Mar 30, 2028
Last update posted
Feb 19, 2026

2024 – 2028

United States locations

U.S. sites
24
U.S. states
18
U.S. cities
22
Facility City State ZIP Site status
Clinical Trial Site Phoenix Arizona 85054
Clinical Trial Site Beverly Hills California 90211
Clinical Trial Site La Jolla California 92037
Clinical Trial Site Stanford California 94305
Clinical Trial Site Washington D.C. District of Columbia 20010
Clinical Trial Site Chicago Illinois 60637
Clinical Trial Site Glenview Illinois 60026
Clinical Trial Site Indianapolis Indiana 46202
Clinical Trial Site Kansas City Kansas 66160
Clinical Trial Site Baltimore Maryland 21287
Clinical Trial Site Boston Massachusetts 02115
Clinical Trial Site Boston Massachusetts 02118
Clinical Trial Site Rochester Minnesota 55905
Clinical Trial Site St Louis Missouri 63110
Clinical Trial Site Omaha Nebraska 68198
Clinical Trial Site New York New York 10029
Clinical Trial Site New York New York 10032
Clinical Trial Site Durham North Carolina 27710
Clinical Trial Site Cleveland Ohio 44195
Clinical Trial Site Columbus Ohio 43214
Clinical Trial Site Philadelphia Pennsylvania 19104
Clinical Trial Site Nashville Tennessee 37232
Clinical Trial Site Dallas Texas 75246
Clinical Trial Site Salt Lake City Utah 84132

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06679946, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 19, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06679946 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →